Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 21, 22 | -0.28
Increased by
+37.78%
|
-0.28 |
Sep 27, 22 | -0.36
Increased by
+10.00%
|
-0.34
Decreased by
-5.88%
|
Sep 23, 22 | -0.36
Decreased by
-28.57%
|
-0.34
Decreased by
-5.88%
|
May 16, 22 | -0.33
Increased by
+17.50%
|
-0.43
Increased by
+23.26%
|
Feb 14, 22 | -0.45
Increased by
+25.00%
|
-0.38
Decreased by
-18.42%
|
Nov 9, 21 | -0.40
Increased by
+33.33%
|
-0.35
Decreased by
-14.29%
|
Sep 23, 21 | -0.28
Increased by
+50.00%
|
-0.40
Increased by
+30.00%
|
May 17, 21 | -0.40
Increased by
+20.00%
|
-0.41
Increased by
+2.44%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jun 30, 22 | 325.00 K
Decreased by
-35.00%
|
-18.39 M
Decreased by
-51.50%
|
Decreased by
-5.66 K%
Decreased by
-133.08%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-14.29 M
Increased by
+3.75%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-19.14 M
Decreased by
-23.81%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-17.12 M
Decreased by
-11.31%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 500.00 K
Increased by
+N/A%
|
-12.14 M
Increased by
+16.32%
|
Decreased by
-2.43 K%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-14.85 M
Decreased by
-32.73%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
-100.00%
|
-15.46 M
Decreased by
-79.31%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 20 | 0.00
Decreased by
N/A%
|
-15.38 M
Decreased by
-32.85%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.